Gao, H. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Bruna, A. A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds. Gao, D. Organoid cultures derived from patients with advanced prostate cancer. Prospective derivation of a living organoid biobank of colorectal cancer patients.
Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Sachs, N. A living biobank of breast cancer organoids captures disease heterogeneity. Vlachogiannis, G. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science , — Izumchenko, E. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.
Hidalgo, M. Patient-derived xenograft models: an emerging platform for translational cancer research. Marangoni, E. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Zhang, X.
To err is human
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Prinz, F. Believe it or not: how much can we rely on published data on potential drug targets? Drug Discov. Begley, C.
Drug development: raise standards for preclinical cancer research. Haibe-Kains, B. Inconsistency in large pharmacogenomic studies. Pharmacogenomic agreement between two cancer cell line data sets. Nature , 84—87 Haverty, P. Reproducible pharmacogenomic profiling of cancer cell line panels.
Franca, T. Reproducibility crisis in science or unrealistic expectations? EMBO Rep. Hunter, P. Baker, M. Reproducibility crisis: blame it on the antibodies. Loken, E. Measurement error and the replication crisis. Horbach, S. The ghosts of HeLa: how cell line misidentification contaminates the scientific literature. Walrath, J. Genetically engineered mouse models in cancer research.
Tschaharganeh, D. FEBS J. Andrechek, E. Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential.
Genome Instability in Cancer Development / Edition 1
Natl Acad. USA , — Van Keymeulen, A. Westcott, P.
- Management and Practice in Emergency Nursing.
- 1. Cellular mechanisms that prevent or promote genomic instability?
- A letter to ... dr. Durell ... occasioned by a late expulsion of six students from Edmund hall.
The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nassar, D.
Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. Ben-David, U. The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis. Herschkowitz, J. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.
Uchimura, A. Germline mutation rates and the long-term phenotypic effects of mutation accumulation in wild-type laboratory mice and mutator mice. Genome Res.
Simon, M. Genome Biol. Mulligan, M.
Genes Brain Behav. Liron, T.
Genome Instability in Cancer Development (Advances in Experimental Medicine and Biology)
Kalish, S. Bourdi, M. Mahajan, V. Mattapallil, M. Jones, C. Comparative genomic hybridization reveals extensive variation among different MCF-7 cell stocks.
Genomic Instability in Cancer Development - Dimensions
Cancer Genet. Coser, K. Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. Nugoli, M. BMC Cancer 3 , 13 Kleensang, A. Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function. Frattini, A. High variability of genomic instability and gene expression profiling in different HeLa clones.
Sato, S. Single-cell lineage tracking analysis reveals that an established cell line comprises putative cancer stem cells and their heterogeneous progeny. Genetic and transcriptional evolution alters cancer cell line drug response. Liu, Y. Genomic, proteomic and phenotypic heterogeneity in HeLa cells across laboratories: implications for reproducibility of research results. Fasterius, E. Analysis of public RNA-sequencing data reveals biological consequences of genetic heterogeneity in cell line populations.
Weissbein, U. Culture-induced recurrent epigenetic aberrations in human pluripotent stem cells. PLOS Genet. Mekhoubad, S. Erosion of dosage compensation impacts human iPSC disease modeling.